● Recruiting

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Condition: Ewing Sarcoma · Colorectal Adenocarcinoma · Sponsor: Inhibrx Biosciences, Inc

PhasePhase 1

Planned participants411

Who can joinAll sexes, 12 Years to 85 Years

Healthy volunteersNo

About this study

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

This description comes directly from the study's public registry record.

Talk to the study team

Study Director, -Inhibrx · 858-500-7833 · clinicaltrials@inhibrx.com

Always discuss trial participation with your own doctor first.

Locations (36)

HonorHealth Research Institute	Scottsdale, Arizona, United States	Completed
Precision NextGen Oncology and Research	Beverly Hills, California, United States	Recruiting
City of Hope	Duarte, California, United States	Recruiting
Valkyrie Clinical Trials	Los Angeles, California, United States	Recruiting
University of California, San Diego (UCSD) - Moores Cancer Center	San Diego, California, United States	Withdrawn
University of California, San Francisco (UCSF)	San Francisco, California, United States	Recruiting
Sarcoma Oncology Center	Santa Monica, California, United States	Recruiting
University of Colorado Hospital	Aurora, Colorado, United States	Recruiting
Emory University - Winship Cancer Institute	Atlanta, Georgia, United States	Recruiting
The University of Chicago	Chicago, Illinois, United States	Completed
University of Michigan	Ann Arbor, Michigan, United States	Recruiting
START Midwest Michigan, PC	Grand Rapids, Michigan, United States	Recruiting

+ 24 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03715933